Long-Term Treatment Outcome of Progressive Mycobacterium avium Complex Pulmonary Disease
Open Access
- 1 May 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (5), 1315
- https://doi.org/10.3390/jcm9051315
Abstract
Background: Multidrug therapy is essential for preventing respiratory failure in patients with highly progressive Mycobacterium avium complex pulmonary disease (MAC-PD). However, the prognosis and long-term outcome following combination therapy is poorly understood. Methods: We retrospectively evaluated the clinical characteristics and long-term outcomes in patients with chemo-naïve progressive MAC-PD, hospitalized for first-line multidrug therapy. Results: Among 125 patients, 86 (68.8%) received standardized treatment (rifampicin, ethambutol, clarithromycin), 25 (20.0%) received a fluoroquinolone (FQ)-containing regimen, and 53 (42.4%) received aminoglycoside injection. The sputum conversion rate was 80.0%, and was independently associated with standardized treatment. The incidence of refractory disease (45.6%) was independently and negatively associated with standardized regimen and aminoglycoside use. Choice of an FQ-containing regimen was not associated with positive outcome. Clarithromycin resistance occurred in 16.8% and was independently associated with refractory disease. MAC-PD-associated death occurred in 3.3% of patients with non-cavitary nodular bronchiectasis (NB) and 21.3% with cavitary MAC-PD over a median follow-up period of 56.4 months. The rates of MAC-PD-associated death were comparable between cavitary-NB and fibrocavitary disease. Concurrent chronic pulmonary aspergillosis (CPA) occurred in 13 (17.3%) patients with cavitary MAC-PD, and age, diabetes mellitus, and CPA were independent risk factors for mortality. Conclusions: Standardized intensive multidrug treatment reduces disease progression and persistence in progressive MAC-PD. Cavitary NB may differ from, rather than being just an advanced stage of, non-cavitary NB. The high incidence and significant mortality of CPA in cavitary MAC-PD highlight the need for early diagnosis and treatment.Funding Information
- Japan Agency for Medical Research and Development (18fk0108043j0002)
This publication has 34 references indexed in Scilit:
- Treatment of Refractory Mycobacterium avium Complex Lung Disease with a Moxifloxacin-Containing RegimenAntimicrobial Agents and Chemotherapy, 2013
- Prognostic Factors of 634 HIV-Negative Patients with Mycobacterium avium Complex Lung DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2012
- A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex diseaseRespiratory Medicine, 2007
- Prospective Analysis of Cystic Fibrosis Transmembrane Regulator Mutations in Adults With Bronchiectasis or Pulmonary Nontuberculous Mycobacterial InfectionSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2006
- The Microbiological and Clinical Effects of Combined Therapy according to Guidelines on the Treatment of Pulmonary Mycobacterium avium Complex Disease in Japan – Including a Follow-Up StudyRespiration, 2006
- A Randomized Evaluation of Ethambutol for Prevention of Relapse and Drug Resistance during Treatment ofMycobacterium aviumComplex Bacteremia with Clarithromycin‐Based Combination TherapyThe Journal of Infectious Diseases, 1997
- A Comparison of Two Regimens for the Treatment ofMycobacterium aviumComplex Bacteremia in AIDS: Rifabutin, Ethambutol, and Clarithromycin versus Rifampin, Ethambutol, Clofazimine, and CiprofloxacinThe New England Journal of Medicine, 1996
- Clarithromycin in the Treatment of Mycobacterium avium Lung Infections in Patients Without AIDSSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1995
- Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease.American Journal of Respiratory and Critical Care Medicine, 1994